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study, a Rasch analysis will be performed and the validation
process will be completed with the remaining measurement prop-
erties (feasibility, validity, reliability and responsiveness to
change) and with a higher number of patients.
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OBJECTIVES: To reduce, score and assess the psychometric
properties of the Freedom from Glasses Value Scale (FGVS), a
new scale developed to measure beneﬁts of freedom from
glasses in cataract and presbyopic patients after multifocal
intraocular lens (IOL) surgery. METHODS: The FGVS, a
21-item Patient-Reported Outcomes instrument, was developed
simultaneously in French and Spanish. It was administered by
phone in a study conducted with 152 French and 152 Spanish
patients who underwent cataract or presbyopia surgery at least
1 year before the interview. Statistical methods (principal com-
ponent analysis, multi-trait analysis) and content analysis were
used to select the items and to score the FGVS. Psychometric
properties (validation of the structure, internal consistency reli-
ability, known-group validity) of the resulting version were
assessed in the pooled population and by country. RESULTS:
One item was removed from the FGVS, three motivation items
were kept but not aggregated in a dimension, and two main
dimensions were deﬁned (‘global evaluation’, 9 items; ‘advan-
tages’, 8 items). These two dimensions contain ﬁve subscores
(‘evaluation of the results’, 2 items; ‘feelings’, 4 items; ‘global
judgment’, 3 items; ‘psychological advantages’, 3 items; ‘prac-
tical advantages’, 5 items). A higher score indicates a higher
beneﬁt from surgery. The scores presented good psychometric
properties; all items met the convergent validity criterion and
only three did not meet the discriminant validity criterion.
Cronbach’s alpha was greater than 0.70 for all dimensions and
sub-dimensions (good internal consistency reliability), and the
FGVS was able to discriminate between patients wearing glasses
or not after surgery (higher scores for patients not wearing
glasses). FGVS scores were signiﬁcantly higher in Spain than in
France, however, they showed similar psychometric perfor-
mances in both countries. CONCLUSIONS: The FGVS is a
valid and reliable instrument measuring beneﬁts of freedom
from glasses perceived by cataract and presbyopic patients after
multifocal IOL surgery.
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OBJECTIVES: To ascertain the scoring and to assess the psycho-
metric properties of the Eye-Drop Satisfaction Questionnaire
(EDSQ). METHODS: The EDSQ was developed to assess the
satisfaction and compliance of patients with glaucoma treatment.
The hypothesised model content of the questionnaire resulting
from patient and clinician interviews organised 43 items into
six domains: Patients characteristics, Treatment characteristics,
Patient-clinician relationship, Patient experience, Patient-
treatment interaction, and Patient knowledge. The EDSQ was
included in a observational, multicenter study in France in
patients treated for glaucoma. The scoring of the EDSQ was
investigated by testing several possible structures, resulting from
the hypothesised model/Factor Analysis. Psychometric properties
of the retained structure were assessed: internal consistency reli-
ability (Cronbach’s alpha) and construct validity (multitrait
analysis). Distributional features (missing data, ceiling and ﬂoor
effects) of the EDSQ scores were scrutinised. RESULTS: Analyses
were performed with 169 patients who had completed more than
half of the EDSQ items. The retained structure, resulting from
Principal Component Analysis, included six domains: Concern
about treatment (5 items), Concern about disease (2 items),
Satisfaction with patient-clinician relationship (5 items), Positive
beliefs (3 items), Treatment convenience (3 items), and Declared
compliance (3 items). Items not included in the domains were
kept for separate analysis. Cronbach’s alpha of the domains was
greater than 0.7 for ﬁve domains and ranged from 0.65 to 0.90.
The structure offered good item convergent and item divergent
validity (range of item-scale correlation: 0.36–0.82). Moderate
ceiling effect was observed for the Satisfaction with patient-
clinician relationship score (20% at maximum score), reﬂecting
good relationships. An important ceiling effect was also observed
for the Declared compliance score, with patients declaring high
levels of compliance (49% at maximum score). CONCLU-
SIONS: The scoring of the EDSQ was developed and the ques-
tionnaire was shown to have satisfactory psychometric
properties.
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CAREGIVER BEHAVIOUR WHEN FACINGTHE DIFFERENT
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OBJECTIVES: To assess the parents’/caregivers’ behavior of the
pediatric patient with atopic dermatitis (AD) stratiﬁed by type,
severity and ﬂare-up area. METHODS: An epidemiological,
cross-sectional study in patients 2–12 years old with mild or
moderate AD and at least two ﬂares in the previous year, were
conducted in 451 paediatric sites. Patient characteristics and a
brief clinical history were asked to caregivers. Data about the
management and characteristics of ﬂares were requested to car-
egivers. The satisfaction with treatment use was also requested.
A logistic regression was performed to analyze the predictive
factors of worries to use corticosteroids. Moreover, the odds
ratio (OR) of them were calculated. RESULTS: A total of 1177
patients were included. A total of 52.3% boys with a mean
(SD) of 5.3(2.8) years old. A total of 66.4% of patients had
family history of AD, two third of them were parents. The
mean (SD) age at diagnosis was 1.6 (1.5). The lesions are
mainly presented in upper and lower extremities and face/neck
(>70%). The parents’/caregivers’ visits to the doctor was six
times greater for moderate episodes vs mild ones (OR = 6.15,
IC95%: 5.12–7.14; p < 0.0001). Regarding visits according to
age, there were an 8% visits decrease for each year of age
(OR = 0.92, IC95%: 0.89–0.96; p < 0.0001). A total of 19.3%
of caregivers never use corticosteroids in lesions on face/neck,
and 52.4% could use it only as an alternative option. However,
when lesions are presented in other parts of body, 48.9% of
caregivers use it as ﬁrst line option. The most commonly used
treatments are moisturizing products (31.0%), topical immuno-
modulators (30.3%) and strong corticosteroids (23.3%). There
are three predictive factors related to avoid use of corticoster-
oids: location in face/neck (OR = 4.47, IC95%: 3.50–5.72),
mild severity (OR = 1.98, IC95%: 1.48–2.66) and low age
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(OR = 0.94, IC95%: 0.88–0.99). CONCLUSIONS: Parents/
caregivers have serious worries to use corticosteroids in chil-
dren with ﬂares in face/neck, with mild severity and in younger
childrens.
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OBJECTIVES: Alternative treatments are available to relieve
people with moderate and severe psoriasis in states of remission
and relapse. The purpose of this study was characterise treat-
ment satisfaction with alternative therapies in a survey across
nine European countries. Speciﬁcally, to determine relative
treatment satisfaction with etanercept. METHODS: Up to 120
subjects with moderate or severe psoriasis were identiﬁed in
each of nine countries: Austria (n = 50), France (n = 120),
Germany (n = 120), Italy (n = 120), The Netherlands (n = 75),
Norway (n = 43), Spain (120), Sweden (n = 50) and the UK
(n = 120). Patients were identiﬁed through their dermatologist,
and selected in order to give a sample that represented the alter-
native current treatment regimens, including: biologics such as
etanercept, systemic therapies, and light therapy (PUVA).
Patients were excluded if they had psoriatic arthritis. Treatment
severity was classiﬁed in two ways. Firstly, self-reported sever-
ity, and secondly; percent bodily coverage with psoriatic
plaques. Satisfaction with treatment was deﬁned as a response
of either “satisﬁed” or “very satisﬁed” with treatment. Treat-
ments were excluded from the analysis where <20 observations
were available. Fumaderm was excluded as it was not relevant
for all countries. RESULTS: There were 818 respondents in
total; 45% male. Their mean age was 40.1 years (sd 11.8), and
the median time since diagnosis was 12.0 years (IQR 4.0 to
21.0). The frequency of psoriasis severity for people with <3%,
3%–10%, and >10% bodily coverage was 74 (9%), 421
(52%), and 323 (39%) people, respectively. Overall, 67% of
people expressed satisfaction with psoriasis treatment (64%
moderate and 71% severe; p = 0.117). For people with moder-
ate psoriasis, 3% to 10% coverage, the following percent of
people reported satisfaction with treatment: cyclosporine 60%
(52 of 87), PUVA 63% (54 of 86), methotrexate 65% (53 of
81) and etanercept 78% (21 of 27; p = 0.387). For people with
severe psoriasis, >10% coverage, treatment satisfaction was
achieved as follows: methotrexate 59% (31 of 53), PUVA 62%
(28 of 45), cyclosporine 70% (19 of 27), remicade 71% (20 of
28) and etanercept 94% (46 of 49; p = 0.001). People with
severe psoriasis were more satisﬁed with treatment with etan-
ercept than moderate psoriasis (78% vs. 94%; p = 0.088).
These ﬁndings were consistent across the nine countries. CON-
CLUSIONS: The majority of people with moderate and severe
psoriasis expressed satisfaction with their current treatment.
Treatment satisfaction with etanercept in both groups was
more frequent when using etanercept (78% and 94%,
respectively).
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OBJECTIVES: To examine ustekinumab’s effects on work limi-
tations, productivity, and the number of workdays missed due to
psoriasis. METHODS: In PHOENIX 2 (a Phase 3 trial), 1,230
patients were randomized 1:1:1 to ustekinumab (45 mg or 90 mg
administered at weeks 0, 4, and q12 weeks), or placebo. Patients
randomized to placebo crossed over to receive ustekinumab
45 mg or 90 mg at week 12. Work limitations were assessed
using the Work Limitations Questionnaire (WLQ). WLQ assesses
work limitations due to health in four areas: physical, time
management, mental-interpersonal, and output demands. Each
demand is scored from 0 (limited none of the time) to 100
(limited all of the time). Productivity was assessed using a Visual
Analog Scale (0–10). The number of workdays missed due to
psoriasis in the last 4 weeks was evaluated at baseline and week
12. RESULTS: At baseline, 75% of patients were employed. At
week 12, the mean changes in scores of physical, time manage-
ment, mental-interpersonal, and output demands were -6.33,
-7.85, -7.67 and -6.09, respectively, in ustekinumab-treated
patients, compared to mean changes of -0.20, 0.74, 1.11, and
1.08, respectively, in the placebo group (p < 0.01, each compari-
son of ustekinumab vs. placebo). The mean change in produc-
tivity score from baseline to week 12 was -2.55 for the combined
ustekinumab group vs 0.0 for the placebo group (p < 0.001). The
mean reduction from baseline to week 12 in the number of
workdays missed in the last 4 weeks in the combined usteki-
numab group was 0.2 days, compared to a reduction of 0.04
days in the placebo group. On an annual basis, this represents a
reduction of 2.1 workdays missed in the ustekinumab group vs.
the placebo group. Patients in the placebo group who crossed
over to ustekinumab at week 12 achieved similar improvements
at week 24 in work limitations, productivity, and workdays
missed compared to patients initially randomized to usteki-
numab. CONCLUSIONS: Ustekinumab signiﬁcantly improved
work limitations, increased productivity, and reduced workday
loss in moderate to severe psoriasis patients.
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PRESCRIPTION REFILLS AND HEALTH CARE COSTS
ASSOCIATED WITHTOPICAL METRONIDAZOLE IN MEDICAID
ENROLLED PATIENTS WITH ROSACEA
Jayawant SS1, Feldman SR2, Balkrishnan R3
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OBJECTIVES: Reﬁll adherence to medications and health care
costs are important factors to consider while making informed
decision regarding treatment of rosacea patients. The objective of
this study was to examine predictors of number of reﬁlls related
to topical metronidazole and total health care costs in rosacea
patients. METHODS: This study utilized a longitudinal cohort
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